Seres Therapeutics, Inc. · NASDAQ:MCRB

Seres Therapeutics — Jefferies Healthcare Conference 2023

27 slides from Seres Therapeutics's conference presentation, Jun 7, 2023

  1. Slide 1: Jefferies Healthcare Conference

    Jefferies Healthcare June 7, 2023 Conference

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to timing of VOWST product availability; the anticipated supply and degree of market acceptance of VOW

  3. Slide 3: VOWST - First FDA Approved Orally Administered Microbiota-Based Therapeutic

    VOWSTTM - First FDA Approved Orally Administered Microbiota-Based Therapeutic Now commercially available VOWSTTM is indicated to prevent the recurrence of C. difficile infection (CDI) in individuals 18 years of age or older following antibacterial treatment for recurrent CDI (rCDI). Seres is pioneer

  4. Slide 4: Seres Mission: Transforming the Lives of Patients Worldwide with Revolutionary Microbiome Therapeutics

    Seres Mission: Transforming the Lives of Patients Worldwide with Revolutionary Microbiome Therapeutics Encapsulated consortia of commensal bacteria designed to target multiple disease-relevant pathways simultaneously Bacterial Consortia Orally-formulated, using current Good Manufacturing Disease Eng

  5. Slide 5: Strategic Priorities | Expanding Microbiome Therapeutic Leadership

    Strategic Priorities | Expanding Microbiome Therapeutic Leadership Successfully commercialize • FDA approved on April 26, 2023 VOWSTTM, first-in-class oral • Commercially available microbiome therapeutic • Co-commercialization agreement with Nestlé Health Science • SER-155 Phase 1b study in allo-HSC

  6. Slide 6: VOWST is the First Approval from Our Pipeline of Oral Microbiome Therapeutics

    VOWST is the First Approval from Our Pipeline of Oral Microbiome Therapeutics INFECTION PROTECTION Preclinical Phase 1b Phase 2b Phase 3 FDA Approval Collaborators VOWST 1,2 Recurrent C. difficile (fecal microbiota spores, live-brpk) Bloodstream and antimicrobial-resistant bacterial infections & 3 S

  7. Slide 7: VOWST and Recurrent C. difficile Infection

    VOWSTTM and Recurrent C. difficile Infection 7 Seres Therapeutics, Inc. © 2023

  8. Slide 8: C. difficile Infections Are an Urgent Public Health Threat

    C. difficile Infections Are an Urgent Public Health Threat Spore-forming, toxin- Symptoms include colitis Acute onset of severe High probability of producing, gram-positive, and severe, watery symptoms leads to recurrence >20%, usually anaerobic bacteria diarrhea with up to 15 hospitalization for wi

  9. Slide 9: VOWST Offers an Attractive Product Profile

    VOWST Offers an Attractive Product Profile Highlights of Prescribing Information Indication statement VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals ✔ Broad product label covering adults with rCDI, including at first recurrence 18 years of age

  10. Slide 10: VOWST is Highly Anticipated by Healthcare Professionals

    VOWST is Highly Anticipated by Healthcare Professionals HCP Intent to Prescribe VOWSTTM “ Recurrent C. difficile infection is a highly debilitating and life-threatening disease, and antibiotics alone do not address the underlying 22% cause of rCDI, dysbiosis of the gut microbiome. The approval of VO

  11. Slide 11: HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences

    HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences and Limitations of Current Options Top 5 rCDI Treatment Goals Top 5 Unmet Needs % Ranked in Top 3 % Ranked in Top 3 Prevention of Preventing subsequent recurrences 59% 66% • Prevention of recurrences is recurrences seen as a top treatm

  12. Slide 12: Co-commercializing VOWST in the United States with 50/50 profit sharing

    Co-commercializing VOWST in the United States with 50/50 profit sharing per July 2021 agreement, extending global strategic collaboration 12 Seres Therapeutics, Inc. © 2023

  13. Slide 13: Combined Field Teams to Cover Highest Potential rCDI Prescribers

    Combined Field Teams to Cover Highest Potential rCDI Prescribers Prioritize top volume and early adopting HCPs: 150-person GI sales force • GI sales force covers 85% of GI practices for current inline Nestle product, ZENPEP • Average 10 years industry experience & 5 years in GI • Drove ZENPEP® accel

  14. Slide 14: Engaging with Key Commercial and Medicare Part D Plans to Initiate Broad Coverage

    Engaging with Key Commercial and Medicare Part D Plans to Initiate Broad Coverage Path to coverage for VOWST Payer mix Up to Launch + 12 months Launch + 18 months Payers utilize NTMBs* to limit Medicare coverage demand begins 37% Medicare 54% Commercial Launch + 12 months 6% Medicaid VOWST Medicaid

  15. Slide 15: VOWST Delivers Compelling Value Proposition; Committed to Broad Patient Access

    VOWST Delivers Compelling Value Proposition We Are Committed to Broad Patient Access Uniquely addresses #1 unmet need of preventing Addresses costly burden of rCDI: $43,000 cost / recurrence, with robust efficacy and an established patient1 safety profile with an orally administered regimen Innovati

  16. Slide 16: Laying the Foundations to Ultimately Transform Standard of Care

    Laying the Foundations to Ultimately Transform Standard of Care Initial Focus Expanded Focus • Increase HCP awareness and • Drive repeat use among higher- trial of an entirely new modality volume HCPs • Provide positive experience • Increase reach to lower-volume HCPs • Enhance hospital outflow • Op

  17. Slide 17: Well Positioned to Supply Commercial Demand at Launch and Beyond

    Well Positioned to Supply Commercial Demand at Launch and Beyond 10+ years of Seres technology & facility investment for anaerobic bacterial therapeutics Seres in-house GMP Manufacturing and Quality Control High-quality CMO support VOWSTTM commercial + Bacthera collaboration provides redundancy and

  18. Slide 18: SER-155 and Infection Protection Franchise

    SER-155 and Infection Protection Franchise 18 Seres Therapeutics, Inc. © 2023

  19. Slide 19: Antimicrobial Resistant Infections - Urgent Public Health Threat

    Antimicrobial Resistant Infections - Urgent Public Health Threat Major burden to society Many high-risk patient populations Declared “one of the • Allogeneic HSCT recipients at risk for world’s most urgent bloodstream infections threats” • Additional patients with suppressed $20 billion excess immun

  20. Slide 20: SER-155 Designed to Modulate Targets that Address Leading Causes of Mortality Following Allo-HSCT

    SER-155 Designed to Modulate Targets that Address Leading Causes of Mortality Following Allogeneic HSCT (allo-HSCT) SER-155 is an investigational 16-strain cultivated SER-155 specifically designed to reduce bacterial consortium optimized using MbTx platform infections and GvHD in allo-HSCT recipient

  21. Slide 21: SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD

    SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD in Allogeneic HSCT • SER-155 is an oral, cultivated consortium, designed to reduce abundance of pathogens linked to infections and Enrollment ongoing in GvHD in allogeneic HSCT recipients* SER-155 Phase 1b •

  22. Slide 22: ESKAPE Pathogen Domination was Rare and Transient in Cohort 1

    ESKAPE Pathogen Domination was Rare and Transient in Cohort 1 ESKAPE pathogen domination* in SER-155 administered subjects observed at rates substantially lower than reference cohort SER-155 Cohort 1 Fig.1 Cumulative Domination Incidence • From HSCT Day 0-30, 11% of patients (1 subject, Fig.1 blue l

  23. Slide 23: SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen

    SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen Unique potential clinical and economic value for allogeneic HSCT patients Substantial impact for patients: Favorable safety profile appropriate for almost 30,000 transplants / year across use across HSCT population US and Europe Do

  24. Slide 24: Seres' Path Forward

    Seres’ Path Forward 24 Seres Therapeutics, Inc. © 2023

  25. Slide 25: Maximizing the Opportunity in Infection Protection

    Maximizing the Opportunity in Infection Protection Broadly Target Antimicrobial Additional Opportunities Resistant • Broad preclinical Infections portfolio • Driving to an additional clinical development Autologous HSCT program in 2023 Cancer Neutropenia • Potentially 2+ Pre-clinical Portfolio addit

  26. Slide 26: Well Positioned to Bring VOWST to Patients and Advance Pipeline

    Well Positioned to Bring VOWST to Patients and Advance Pipeline 3/31/2023 cash balance: $106.5 million $125 million milestone received Secured up to $250 million debt facility; following VOWST approval $110 million funded at closing1 Replaces existing debt facility 3/31/2023 pro-forma cash balance:

  27. Slide 27: Continued Microbiome Therapeutic Leadership, Anticipated Growth and Value Creation

    Continued Microbiome Therapeutic Leadership, Anticipated Compelling Growth and Value Creation 2023 2025 • VOWSTTM transforming standard of care for a VOWSTTM approved; broad population of rCDI patients commercialization underway in rCDI • SER-155 in late-stage clinical development • 2+ additional In

Seres Therapeutics — Jefferies Healthcare Conference 2023 on 6ix